What is Neuron23?
Neuron23 is a pioneering biotechnology firm dedicated to the development of precision medicines for genetically defined neurological and immunological diseases. By integrating advanced human genetics with a proprietary artificial intelligence-enabled drug discovery and biomarker platform, the company identifies and validates novel therapeutic targets with high precision. Its research focus spans a critical spectrum of medical needs, including neurodegenerative disorders, neuroinflammatory conditions, and systemic autoimmune diseases. This multidisciplinary approach allows Neuron23 to navigate the complexities of human biology, aiming to deliver transformative treatments for patients suffering from devastating, high-unmet-need conditions.
How much funding has Neuron23 raised?
Neuron23 has raised a total of $310M across 4 funding rounds:
Series B
$80M
Series A
$33.5M
Series C
$100M
Series D
$96.5M
Series B (2020): $80M with participation from Perceptive Advisors, Cowen Healthcare Investments, Redmile Group, Acorn Bioventures, HBM Partners, Kleiner Perkins, Surveyor Capital (a Citadel company), and Westlake Village BioPartners
Series A (2020): $33.5M led by Kleiner Perkins and Westlake Village BioPartners
Series C (2022): $100M supported by Perceptive Advisors, Kleiner Perkins, Surveyor Capital, Acorn Bioventures, HBM Partners, SoftBank Group Corp, Redmile Group, Westlake Village BioPartners, and Cowen Healthcare Investments
Series D (2025): $96.5M featuring Acorn Bioventures, HBM Healthcare Investments, Redmile Group, Softbank Vision Fund, Westlake Village BioPartners, Kleiner Perkins, and Blue Owl
Key Investors in Neuron23
Kleiner Perkins
A Menlo Park-based venture capital firm that invests in early and growth-stage technology and life science companies, providing operational support from seed through IPO.
Acorn Bioventures
An investment firm focused on small-cap public and private biotechnology companies, providing flexible capital across the entire spectrum of development.
Redmile Group
A New York-based private equity and venture capital firm specializing in the healthcare and life sciences sectors.
What's next for Neuron23?
With the successful closure of its latest financing, Neuron23 is poised to enter a critical phase of operational scaling and clinical validation. The influx of capital will likely be directed toward advancing its lead candidates through clinical trials and further refining its AI-driven discovery infrastructure. As the company matures, the focus will shift toward establishing strategic partnerships and potentially preparing for future public market entry. The continued support from its core investor base suggests a long-term commitment to building a sustainable, multi-billion-dollar enterprise capable of reshaping the landscape of precision medicine in neurology and immunology.
See full Neuron23 company page
